Article Index by Subject Category

**JMCP—July/August 1995 through November/December 2006**

### Adherence, Compliance, and Persistence
- Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. 2002;8(3):186-91.
- Adherence, compliance, and persistence in drug therapy. 2002.;8(3):177-78.
- Evaluating medication adherence: which measure is right for your program? 2000;6(6):499-504.

### Adverse Drug Events
- Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. 2001;7(5):402-06.

### Behavioral Health

### Biotechnology

### Capitation and Risk-Financing Methods

### Clinical Pharmacy—Patient Consultation

### Clinical Pharmacy—Payment for Services
Clinical Pharmacy Interventions—Quality, Service, and Cost Outcomes

- Experience with a clinical decision support system in community pharmacies to recommend narrow-spectrum antimicrobials, nonantimicrobial prescriptions, and OTC products to decrease broad-spectrum antimicrobial use. 2006;12(5):390-97.
- Assessment of patient satisfaction with telephone and mail interventions provided by a clinical pharmacy cardiac risk reduction service. 2005;11(5):403-09.
- Clinical pharmacist interventions to bridge the quality chasm and methods necessary to hold quality improvement gains (editorial). 2004;10(2):167-68.
- Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. 2003;9(3):269-73.
- Determining the value of pharmacy services—the search for rigorous research designs. 2002;8(2):152-53.

Clinical Pharmacy Quality Improvement—Patient Safety and Prevention of ADEs

- Preventing medication errors and adverse drug events. 2003;9(1):92-93.

Clinical Practice Guidelines (CPGs) and Quality Improvement

- Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. 2006;12(8):656-64.
- Evidence-based medicine: beware of results from randomized controlled trials and research with administrative claims data (editorial). 2005;11(2):172.
- Crossing the quality chasm—incremental change through clinical practice guidelines (CPGs) (editorial ). 2002;8(5):400-01.
Clinical Quality Improvement

- Framework for pharmacy services quality improvement—a bridge to cross the quality chasm. 2004;10(1):60-78.
- Managing drug therapy decisions: pay me now or pay me later. 1998;4(3):242, 245.

Collaboration—Pharmacists and Others

- Pharmacy practice in the long-term care environment. 1997;3(2):189-94.

Collaboration—Pharmacy Education

- Oregon State University partners with Medicaid and a managed care organization. 2001;7(3):185-86.
- The University of Colorado School of Pharmacy and the University of Colorado Health Plan forge a PBM partnership. 1998;4(5):478, 480.

Collaborative Practice—Pharmacists as Prescribers


Database Analyses of Drug Utilization

(see also Research Methods)

- Categorizing patients from medical claims data—the influence of GIGO (letter). 2004;10(6):559-60.
- Claims data and drawing appropriate conclusions. 2002;8(2):152.

Decision Support Systems (DSS)


Direct-to-Consumer Advertising (DTCA)

(see also Drug Promotion and Advertising)

- United States, the last venue for direct-to-consumer advertising, props up the erectile dysfunction market (editorial). 2005;11(2):176-78.
- Direct-to-patient advertising (DTPA) and direct-to-consumer advertising (DTCA) of prescription drugs. 2002;8(6):521.

Disease Management—Airway Disease or Allergic Rhinitis

- Health care utilization determined from administrative claims analysis for patients who received inhaled corticosteroids with either montelukast or salmeterol (letter). 2006;12(6):486-87.
Article Index

- Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. 2006;12(4):310-21.
- Selectivity and specificity are the keys to cost-effective use of omalizumab for allergic asthma (editorial). 2005;11(9):774-76.
- Evaluation of omalizumab from a health plan perspective. 2005;11(9):735-45.
- New concepts to improve health outcomes for patients with chronic obstructive pulmonary disease (supplement). 2005;11(6, S-a):S1-S22.
- Contemporary issues in the care of patients with chronic obstructive pulmonary disease (supplement). 2005;11(5, S-a):S1-S16.
- Evaluating asthma medication use before and after an acute asthma-related event. 2001;7(4):303-08.

Disease Management—ALS (Amyotrophic Lateral Sclerosis)

Disease Management—Alzheimer’s Disease

Disease Management—Angina, ACS, CHD, and CHF
- Total first-year costs of acute coronary syndrome in a managed care setting. 2005;11(4):300-06.

Disease Management—Arthritis and Joint Pain
- Review of eight pharmacoeconomic studies of the value of biologic (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. 2006;12(7):555-69.
• COX-2 inhibitors: little or no GI protection, increased risk of cardiovascular events, high cost, and other class-less effects (editorial). 2005;11(7):590-93.
• Gastrointestinal bleeding rates among managed care patients newly started on COX-2 inhibitors or nonselective NSAIDs. 2005;11(7):550-58.
• Relationship of clinical factors to the use of COX-2 selective NSAIDs within an arthritis population in a large HMO. 2002;8(4):252-58.
• Economic considerations in the management of arthritis. 1999;5(6):476-78, 481-82, 484.

Disease Management—Atopic Dermatitis
• The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. 2002;8(5):333-42.

Disease Management—Attention-Deficit/ Hyperactivity Disorder (ADHD)
• Physician perceptions of the use of medications for attention deficit hyperactivity disorder. 2003;9(5):416-23.

Disease Management—Benign Prostatic Hyperplasia

Disease Management—Cancer
• Pharmacy benefit spending on oral chemotherapy drugs. 2006;12(7):570-77.

Disease Management—Depression or Bipolar Disorder
• Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. 2006;12(1):43-54.
• Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. 2005;11(3):220-30.
• Depression in corporate America: an integrated care approach to increase productivity and improve outcomes (supplement). 2005;11(3):S1-S23.
• Evidence-based medicine: are SSRIs more effective than placebo and what length of therapy is enough? (editorial). 2005;11(2):172-76.
• Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy—results from a managed care administrative claims database. 2005;11(2):145-50.
• Documentation of indicators for antidepressant treatment and response in an HMO primary care population. 2000;6(6):494-98.
• Utilization patterns of antidepressant medications in a patient population served by a primary care medical group. 1999;5(3):243-49.

Disease Management—Diabetes
• Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. 2006;12(8):649-55.
• Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. 2006;12(7):548-54.
• What are incretins, and how will they influence the management of type 2 diabetes? (supplement). 2006;12(7, S-a):S1-S16.
• Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. 2006;12(6):466-71.
• Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive therapy in MCO patients with type 1 or type 2 diabetes. 2006;12(4):303-09.
• Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. 2006;12(2):130-42.
• Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population. 2006;12(2):121-29.
• Relationship of glycemic control to total diabetes-related costs for managed care plan members with type 2 diabetes. 2005;11(7):559-64.
• Importance of blood glucose monitoring to achieve short- and long-term glycemic control. 1999;5(6):543-47.
• Use of glycosylated hemoglobin testing among patients with diabetes mellitus. 1997;3(6):691-96.

Disease Management—Dyslipidemia

• Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. 2006;12(9):745-51.
• Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA medical centers. 2005;11(9):763-71.
• Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. 2005;11(8):681-86.
• Fish oil for heart disease—happy to be in second place (editorial). 2005;11(7):584-85.
• Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. 2005;11(6):499-504.
• Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. 2004;10(3):244-50.
• Effective cholesterol management with fewer dollars. 2002;8(6):519.
• High blood cholesterol and ATPIII: guidelines for health benefit and health care providers. 2001;7(6):482-89.

**Disease Management—Heartburn**

- Employers need to have a wider horizon than drug costs alone when considering the implementation of health care intervention programs (letter and author response). 2006;12(7):581-83.
- PPIs are therapeutically interchangeable and ideal for a managed care intervention such as therapeutic MAC (editorial). 2006;12(7):578-80.

**Disease Management—Hypertension and Cardiovascular Disease**

- Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. 2005;11(9):727-34.
- Impact of the ALLHAT study results on managed care. 2003;9(1):84-86.

**Disease Management—Irritable Bowel Syndrome**


**Disease Management—Kidney Disease**

- Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting. 2006;12(9):714-25.

**Disease Management—Migraine Syndrome**

Disease Management—Obesity

- Which is more elusive, the pot of gold at the end of a rainbow or determining the most cost-effective triptan? (editorial). 2005;11(6):513-15.
- Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. 2005;11(5):394-402.
- Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. 2003;9(1):45-52.

Disease Management—Multiple Sclerosis


Disease Management—Osteoporosis


Disease Management—Psoriasis

- Fluoroquinolone-use evaluation by acute cystitis. 1996;2(5):564-68.

Disease Management—Otitis Media and Infectious Disease

Article Index

Disease Management—Seizure Disorders and Epilepsy
- Step therapy is not appropriate for antiepileptic drugs (letter). 2006;12(3):269-70.

Disease Management—Thrombosis, DVT, and VTE
- Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. 2005;11(9):755-62.
- In search of safe and effective oral anticoagulation (editorial). 2005;11(8):704-08.
- Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. 2005;11(8):663-73.

Disease Pathology

Dose Optimization
- Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program. 2006;12(6):449-56.
- Randomized controlled trial of a dose consolidation program. 2004;10(5):396-403.
- Dose optimization: an opportunity for pharmacy administrative services. 2002;8(2):81.

Drug Benefit Management—Benchmarks and Measures
- Principles and practical applications of benchmarking (supplement). 2005;11(1, S-a):S1-S23.
- Other DACON observations—community pharmacists do not intentionally transmit incorrect claim information—but caution is warranted in days supply calculations (letter). 2004;10(2):174-75.
- Searching for drug benefit benchmarks—cost per day of therapy. 2002;8(1):54-55.

Drug Benefit Management—Benefit Design
- Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share. 2006;12(8):665-76.
- Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit. 2006;12(5):377-82.
- A 30-month evaluation of the effects on cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. 2006;12(1):25-32.
- The role of pharmaceuticals in reducing cardiometabolic risk: rethinking pharmacy benefit design to reduce the burden on the health care system (supplement). 2006;12(1):S1-S16.
• Prescription use behavior among Medicare beneficiaries with capped prescription benefits. 2002;8(5):360-64.

**Drug Benefit Management—Efficiency and Patient Safety**

• Weight uniformity of split tablets required by a Veterans Affairs policy. 2003;9(3):401-07.
• Mail-order prescriptions requiring clarification contact with the prescriber: prevalence, reasons, and implications. 2003;9(4):346-52.
• Tablet splitting to improve the value-for-money equation in cholesterol management. 2002;8(6):519.
• A model to estimate drug plan cost savings from a trial prescription program. 2001;7(5):391-401.
• Pharmacy benefit administration options. 1996;2(3):272-78.

**Drug Benefit Management—Employee Benefits and Coverage (see also Drug Benefit Management—Benefit Design)**

• Shifting the focus from cost to value: key stakeholder perspectives (supplement). 2006;12(6, S-b):S1-S26.
• Older adults’ drug benefit beliefs: a focus group study. 2005;11(1):77-85.
• Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations (supplement). 2004;10(3, S-a):S1-S20.
• New generic and OTC drugs provide opportunities for drug benefit managers. 2002;8(6):520.
• Analysis of the movement of prescription drugs to over-the-counter status. 2002;8(6):499-508.
• Employer-sponsored health care services. 2001;7(3):189-92.
• Successful disease management programs for health and welfare fund union groups. 1998;4(3):269-70, 272.

**Drug Benefit Management—Patient Satisfaction, Benefit Knowledge, and Consumer Behavior**

• Unraveling the effects of tier-copayment drug benefit designs. 2003;9(2):177-78.
• Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. 2003;9(2):123-33.
• Consumer preferences for types of cost containment in prescription drug programs. 2002;8(3):192-98
• Drugs, PPOs, tiered cost-share for beneficiaries, and consumer preferences. 2002;8(3):177.
• Patient satisfaction with and knowledge of their prescription drug coverage. 2001;7(1):34-42.
• A comparison of satisfaction with mail versus traditional pharmacy services. 1997;3(3):327-37.

**Drug Benefit Management—Pharmacy Providers**


**Drug Benefit Management—Quantity Limits, Step Therapy, and Prior Authorization (PA) and Rebates**

• Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. 2005;11(8):674-80.
• The Academy of Managed Care Pharmacy's Concepts in Managed Care Pharmacy: prior authorization and the formulary exception process (letter). 2005;11(4):358-61.
• Step-therapy edits for PPIs and COX-2 drugs—what we do and do not know (editorial). 2004;10(4):356.
• Evaluation of a monthly coverage maximum (drug specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. 2003;9(4):335-45.
• Prior authorization to manage drug utilization and costs. 2003;9(1):95.
• Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. 2003;9(1):36-44.
• A neurologist's perspective on quantity limits. 2002;8(3):184.
• Triptan quantity limits. 2002;8(3):182-84.
• Medical and pharmacy cost and utilization outcomes of a quantity limit on 5-HT1 agonists (triptans) by a managed care organization. 2001;7(6):468-75.

**Drug Benefit Management Methods—Benefit Design**

• Benefit maximums versus drug benefit needs for Medicare beneficiaries. 2002;8(5):402-03.
• Prescription use behavior among Medicare beneficiaries with capped prescription benefits. 2002;8(5):360-64.

**Drug Promotion and Advertising (see also Direct-to-Consumer Advertising [DTCA])**

• Health care communications agencies respond to managed care. 1998;4(1):9-12.
• Information requirements of health systems as drug purchasers: does the FDA have a role in setting evidentiary standards? 1996;2(6):593-98.

**Drug Spending, Utilization, and Cost Trends**

• Drug costs out of control—check your assumptions. 2002;8(2):81.
• Too much or too little? The role of pharmaceuticals in the health care system. 1999;5(4):296-97, 301-02.
Local area market dynamics. 1998;4(2):115-17, 120.

Drug Therapy—Natural Products

Drug Therapy, Therapeutic Selection, and P&T Decision Making
- Pharmacist intervention in safe and effective conversion of brand to generic drugs (letter). 2005;11(9):777.
- Comparison of costs and utilization between users of insulin lispro versus users of regular insulin in a managed care setting. 2005;11(5):376-82.
- Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users. 2003;9(3):263-68.
- Improvements in glycemic control in type 2 diabetes patients switched form sulfonylurea coadministered with metformin to glyburide-metformin tablets. 2003;9(3):256-62.

Drug Utilization Review (DUR)
or Drug Utilization Management—Appropriate Drug Use

• Comparison of rates of potentially inappropriate medication use according to the Zhan criteria for VA versus private sector Medicare HMOs. 2006;12(5):362-70.


• Longitudinal analysis of the use of etanercept versus inhaled budesonide determined from medical chart audit. 2004;10(6):538-42.


• Frequency of simvastatin prescriptions with potentially interacting medications in a Veterans Affairs health care system. 2004;10(3):239-43.


• Gabapentin may be appropriate for off-label uses (editorial). 2003;9(6):569-70.

• Examination of the evidence for off-label use of gabapentin. 2003;9(6):559-68.


• Analysis of medication use patterns: apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression, and CHF. 2003;9(3):232-37.

• Gabapentin and indications of appropriate use. 2002;8(4):293-94.


• High frequency of itraconazole prescriptions with potentially interacting medications in a large health care plan. 2002;8(3):199-203.


Ethics


Formulary Management—Methods and Effects—Pharmacoeconomics


• P&T committees—black boxes versus AMCP Format, and what is the true cost and value of pimecrolimus (editorial). 2005;11(1):93-94.


• The role of pharmacy benefit managers in formulary design: service providers or fiduciaries? (letter). 2004;10(4):359-60.


• Industry’s perception of presenting pharmacoeconomic models to managed care organizations. 2003;9(2):159-67.
• Summary quality scores for pharmacoeconomic studies: balancing validity with need. 2003;9(1):87-88.
• Examining the value and quality of health economic analyses: implications of utilizing the QHES. 2003;9(1):53-61.
• Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. 2003;9(1):45-52.
• Exploring the methodological challenges of investigating comparison groups with different underlying characteristics: a case study. 2002;8(5):353-59.
• AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. 2001;7(4):272-82.
• The pros and cons of formularies. 2000;6(3):203-07.
• The role of pharmacoeconomic information in the formulary decision-making process. 2000;6(2):108, 113-14, 117-18, 121.
• Outcome analysis of a formulary transition from nifedipine to felodipine at a Veterans Affairs Medical Center. 1999;5(5):425-28.
• Formulary management by an on-site school of pharmacy faculty member in a Medicaid managed care organization. 1998;4(4):407-10.
• DOD's Pharmacoeconomic Center: translating research into good patient care practices. 1997;3(6):662-64, 666.
• Drug formularies: real opportunities to improve MCO efficiency. 1997;3(3):254, 375-76.
• Using outcomes as a tool to evaluate formulary selection decisions: hypercholesterolemia as a case example. 1996;2(4):396-404.

Formulary Management—P&T Committees


Health Care Delivery

• A review of the use of CAM therapy and the sources of accurate and reliable information. 2005;11(8):695-703.
• Development of a complementary and alternative medicine (CAM) pharmacy and therapeutics (P&T) subcommittee and CAM guide for providers. 2005;11(3):252-58.
• International markets offer new opportunities for MCOs and PBMs. 1997;3(4):403-04, 409-10.
• Integration takes managed care in different directions: horizontal, vertical, and beyond. 1997;3(3):260, 263-64.
• Alternative medicine in managed care pharmacy. 1997;3(1):77-80, 83-86.
• Indian Health Service: paving the way for pharmaceutical care. 1997;3(1):36,41-43.
• While health care evolves, antitrust law endures. 1996;2(6):679-86.

Health Care Quality Improvement

• Information technology to cross the quality chasm. 2002;8(5):401-02.
• Quality improvement opportunities in health care—making it easy to do it right. 2002;8(5):394-99.
• Quality measures: looking in all the wrong places. 2001;7(2):88.

www.amcp.org    Vol. 12, No. 9    November/December 2006    JMCP    Journal of Managed Care Pharmacy
• Medical and medication errors: a partial summary of reports by the Institute of Medicine and the quality interagency coordination task force. 2001;7(1):62-68.
• How to evaluate disease state management programs. 1997;3(3):270, 273-74, 277-78.
• Managed care and the quest for quality measures. 1997;3(3):255, 258-89.
• Successful CQI-based programs in a group-model managed care setting. 1995;1(2):134, 137.

Health Care Spending and Health Economics
• Is there no prescription to decrease health care outlays in the face of an aging population? 2000;6(6):450-51.
• Health economics II: some unique aspects of health economics. 2000;6(2):173-78.

Health Insurance and Health Care Finance
• Direct contracting: the next purchaser strategy. 1996;2(1):11-12, 14, 16.

Institutional Managed Care
• Managed pharmaceutical care within a criminal justice system. 2001;7(3):182.

Internet Pharmacy
• Concern about foreign-source pharmacy Internet providers. 2001;7(3):335-36.
• The Internet and PBMs: new business model or business as usual? 2000;6(2):102, 105-07.

Lifestyle Drugs

Managed Care Pharmacy Practice
• Quality articles require peer reviewers—as well as authors (letter). 2005;11(2):186.
• John Ogden talks about managed care in the Veterans Administration. 2002;8(2):91-93.
• Managed care and the pharmacy profession revisited. 1999;5(2):78.
• The importance of communication skills for the managed care pharmacist. 1998;4(2):102.
• The changing face of managed care pharmacy and the role of PBMs. 1997;3(5):494, 497-98.
• Blue Cross and Blue Shield: making pharmaceutical care a key component of managed care. 1996;2(1):33-34, 36, 38.
• Professional opportunities in managed care pharmacy. 1995;1(2):80, 82, 86-87.

Managed Health Care
• Medicare PPOs and managed care. 2003;9(1):91.
• Examining the managed health care continuum. 1997; 3(3):511-12, 515-16, 518.

Manpower and Job Satisfaction
• A closer look at pharmacy technicians. 2003;9(1):84.
• How many pharmacists are in our future? The Bureau of Health Professions projects supply to 2020. 2000;6(6):474-82.
• Burnout in a sample of HMO pharmacists using the Maslach Burnout Inventory. 1998;4(3):495-503.

Medicaid

Medicare and Medication Therapy Management (see also Drug Benefit Management Methods—Benefit Design)
• Timeline and potential impact of CMS’s drug Competitive Acquisition Program (CAP). 2006;12(3):263-64.
• Medication Therapy Management Services for long-term care patients: no road maps for those trying to find their way (editorial). 2005;11(7):586-87.

Pain Management
• Beyond narcotics for effective pain management. 2003; 9(2): 175-76.
• It’s a pain. 1999;5(6):558.

Pharmaceutical Industry and Marketing
• Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. 2005;11(9):746-54.
• India’s pharmaceutical industry: a growing influential force in the world pharmaceutical market. 2002;8(3):211-15.

Pharmacogenomics
• Drug therapy customized to individual patients. 2002;8(4):296-97.
• Health care professionals’ perceptions of the role of pharmacogenomic data. 2002;8(4):278-84.

Pharmacy Education
• Managed care and the University of Texas College of Pharmacy. 2001;7(6):490.
Article Index

• University of Michigan College of Pharmacy and managed care partner to enhance drug therapy. 2001;7(5):345-46.
• An inside look at the benefits of a student pharmacy and therapeutics (P&T) committee competition from the University of Illinois at Chicago. 2001;7(4):259-60.
• Managed care concepts prominently featured in innovative management programs at Duquesne University. 2001;7(2):94,96.
• Synergy between the University of Louisiana at Monroe and the Louisiana Drug Utilization Review Board. 2000;6(5):420.
• College offers certified managed care pharmacist program. 2000;6(3):262-63.
• The University of Maryland's Center on Drugs and Public Policy. 2000;6(2):184-85.
• Managed care pharmacy practice at the Texas Tech University Health Sciences Center School of Pharmacy. 1999;5(6):556-57.
• Description of a formal affiliation between a school of pharmacy and a managed care organization. 1999;5(5):433-37.
• Students gain exposure to managed care principles at a new school of pharmacy. 1999;5(4):371.
• Improving efficiency and effectiveness in managed care: ongoing efforts at the University of New Mexico College of Pharmacy. 1999;5(2):111.
• First managed care pharmacy course at the University of Illinois at Chicago. 1998;4(1):80-81.
• Linking the ivory tower and real-world practice: building a synergy bridge in managed care pharmacy. 1997;3(1):107-08, 110.
• Pharmacy internship offers real-world exposure to managed care pharmacy practice. 1996;2(6):605-06.
• Managed care pharmacy at the St. Louis College of Pharmacy. 1996;2(4):439, 442.
• Managed care pharmacy education at the University of Washington School of Pharmacy. 1996;2(3):319-20.
• Managed care pharmacy education at MCP. 1996;2(1):53.

Physician Education-Intervention—Academic Detailing

• Selection bias in physician education-intervention programs. 2002;8(2):82.
• Driving market share in an integrated health system without therapeutic interchange. 2001;7(4):283-86.
• UIC students mobilize first student chapter of AMCP. 1995;1(3):185-86.

Population Health—Interventions and Prevention of ADEs

• Suboptimal pneumococcal pneumonia vaccination rates among patients at risk in a managed care organization in Israel. 2006;12(3):152-56.

Prior Authorization (PA) (see Drug Benefit Management—Quantity Limits, Step Therapy, and Prior Authorization [PA])

Privacy of Health Information

• The Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the pharmacy benefit: implications for health plans, PBMs, and providers. 2003;9(1):66-71.
• Employer access to employee prescription records: dilemmas for pharmacists. 1997;3(5):504-05, 508.
Quality Assurance


Research Methods

(see also Survey Methods)


Safety—Health Care Worker


Safety—Patient Care (see Drug Utilization Review [DUR])

Specialty Pharmacy

- Specialty pharmacy cost management strategies of private health care payers. 2006;12(9):736-44.
- The emergence of specialty pharmacy. 2000;6(4):280-84.

Survey Methods

(see also Research Methods)

- Constructing mail survey questionnaires to maximize the rates of return and assure the validity and reliability of responses. 2002;8(3):225-31.

Technology—Automation


Technology—Education and Information

- Use of technology throughout the curriculum. 2002;8(2):86.

Technology—Electronic Prescribing

- Standardization is necessary in the methods to assess the value of electronic prescribing systems (letter). 2005;11(7):594-95.

Therapeutic Interchange—Therapeutic Selection
• Utilization of pharmacy claims data to evaluate therapeutic interchange programs. 1999;5(4):331-34.

Value of Pharmacotherapy
• RxHealthValue offers three recommendations and cost research. 2001;7(1):17-20.

Women’s Health